Ingredients & Formulation
Koi Peptides Launches Wholesale Program for Biotech R&D Labs
The program is positioned strictly for research use, keeping it outside finished-formulation and dietary supplement cha…
All 681 stories
Science & Research
Kyowa Kirin Presents Mogamulizumab Data at 2026 WCCL
Four oral presentations and one poster will feature patient-reported outcomes and real-world utilization data for the b…
Science & Research
Vadadustat Patent Portfolio Expands with Orange Book Listing
The moves extend market exclusivity for the HIF-PHI anemia treatment, with implications for branded finished-formulatio…
Regulatory & Policy
FDA Grants Orphan Drug Status to Low-Sodium Oxybate for Sleep Disorder
The designation hinges on a plausible clinical superiority argument over existing oxybate therapies — a regulatory path…
Ingredients & Formulation
Harrow Re-Launches Cyclosporine Eye Emulsion for Pediatric VKC
The prescription re-entry addresses a documented gap in pediatric ophthalmic allergy care, though the product falls out…
Functional Foods & Beverages
Glucosamine-Chondroitin Complex Targets Senior Dog Joint Health
The pet supplement segment is among the fastest-growing categories in functional nutrition, with joint health leading S…
Condition-Specific Health
Gain Therapeutics CEO to Present at Neuro Summit
The clinical-stage biotech is advancing allosteric small molecule therapies — a mechanism drawing growing interest from…
Industry & Business
GEN Restaurant Group Inks Distribution Deal with UNFI
The partnership signals growing foodservice-to-retail crossover as better-for-you restaurant brands pursue broader omni…
Condition-Specific Health
CONNECTA Therapeutics Advances CTH120 Neuroplasticity Trial
The rare CNS indication sits outside core nutraceutical channels, but neuroplasticity modulation is an emerging mechani…
Ingredients & Formulation
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
Cellectis' experimental allogeneic CAR-T therapy lasme-cel receives FDA fast-track designation for treating patients wi…
Ingredients & Formulation
Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire
Cellectis's allogeneic CAR-T therapy lasmé-cel receives FDA advanced therapy status for treating relapsed or refractory…
Ingredients & Formulation
UFC Champion Alex Pereira Launches Chama Ahead of Historic White House Title Fight
UFC Champion Alex Pereira launches Chama, a premium nutraceutical brand, coinciding with his White House title fight bi…